IMU 9.26% 5.9¢ imugene limited

Media Thread, page-12183

  1. 3,199 Posts.
    lightbulb Created with Sketch. 6988
    LC said “ it has an opportunity to obliterate cancer types that have never been touched before”

    ” we’ve got multiple tumors types “

    then she said “ even in this dose escalation stage we can open up many different indications with this therapeutics.”

    In investor lngueage. We should be looking at several more breakthrough therapies designations.


    They are trialling cancers that NO therapeutics have touched before. We might end up with multiple indications similar to Bile Duct cancer. Imagine 5 more Breat through designations needing only 10 Pax per designation. In the other video she talks about expanding the trials.

    Certainly looks like a big year.

    Sounds
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.